BCLI
BRAINSTORM CELL THERAPEUTICS INC.
NASDAQ · Healthcare · Biotechnology · US
$0.90
−8.16%Margins
Gross margin
—
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
90.7%
Return on equity
-2229.2%
Return on assets
97.3%
Return on invested capital
0.00x
Asset turnover
-$4.1M
Cash from operations
$0.00
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026